

Take the next step in improving clinical outcomes

Small community hospitals face unique challenges, most importantly making sure their patients receive the best care possible.

That often begins in the lab, where treatment depends on timely and accurate test results. When those results are wrong, quality of care plummets while the risk of antibiotic misuse and hospital-acquired infections (HAIs) soars.

2 million



people a year become infected with bacteria that are resistant to antibiotics

Source: The Lancet Infectious Diseases



Up to 50% of antibiotics prescribed in acute care hospitals are unnecessary or inappropriate

Source: Centers for Disease Control



Only 26% of small hospitals have met all of the CDC's core elements for ASP programs


Source: Centers for Disease Control

More than

32%

of the bacteria responsible for 2 million HAIs each year are resistant to at least one commonly used antibiotic

Source: Centers for Disease Control




HAIs have increased by **36%** over the past **20 years**

Source: The Lancet Infectious Diseases



23,000 Americans die from an antibiotic-resistant infection each year

Source: The Centers for Disease Control



McKesson can help you take control with lab solutions that support improved quality of care for your patients

We are uniquely positioned to help labs like yours accurately diagnose illnesses, prevent HAIs and improve patient care. Our Antibiotic Stewardship Program delivers **aggressive diagnostics**, **coordinated data** and **change management support** that can help you:

- Improve turnaround time from days to hours
- Save on drug costs by using targeted therapy
- Deliver on Value-Based Care core metrics including reduced length of stay, HAIs and readmission rates
- Improve operational and financial efficiency
- Aggregate data for the clinical team



“Antibiotic stewardship is huge right now. Reducing antibiotic misuse, IV to PO, hospital acquired infections — all of that is really important.”

— Assistant Pharmacy Director, Small Community Hospital, Southeast

Better clinical outcomes begin with better technology

McKesson has teamed up with ILÚM to deliver state-of-the-art technology that unlocks the full potential of clinical and microbiological data. This infectious disease platform supports patient management decisions, quality programs and better outcomes in infectious disease.

ILÚM’s precision antibiotic therapy (PAT) software predicted susceptibility better than the antibiogram in 81% of **clinically meaningful big-drug combinations**, which can lead to improved empiric antibiotic selection.

Implementation of ILÚM in combination with rapid diagnostic technology (RDT) **improved the median time of the antibiotic change by 12 hours** when compared to the RTD alone.

ILÚM has been leveraged by hospitals to **identify previously unknown antimicrobial stewardship opportunities**, including de-escalation, dual-anaerobic therapy and IV to PO.

For more information on how our lab solutions can address your challenges, visit mms.mckesson.com/lab-resources.

